Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial

Published:2018-09-27 Issue:13 Volume:132 Page:1452-1454
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Russell Nigel¹,Burnett Alan²,Hills Robert³,Betteridge Sophie³,Dennis Mike⁴,Jovanovic Jelena⁵,Dillon Richard⁵,Grimwade David⁵

Affiliation:

1. Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom;

2. Department of Haematology, Cardiff University School of Medicine, Cardiff, United Kingdom;

3. Centre for Trials Research, Cardiff University, Cardiff, United Kingdom;

4. Haematology and Transplant Unit, The Christie, Manchester, United Kingdom; and

5. Department of Medical and Molecular Genetics, King’s College Medical School, London, United Kingdom

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/132/13/1452/1467180/blood851824.pdf

Reference7 articles.

1. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial;Burnett;Lancet Oncol,2015

2. Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial;Burnett;Leukemia,2013

3. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials;Kottaridis;Blood,2001

4. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia;Lo-Coco;N Engl J Med,2013

5. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 Trial;Platzbecker;J Clin Oncol,2017

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Leucocytosis during induction therapy with all‐trans‐retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment‐related complications;British Journal of Haematology;2024-09-14

2. Therapy-related myeloid neoplasms following curative treatment of acute promyelocytic leukemia: incidence, correlation with therapeutic regimen, and future directions;Journal of Hematopathology;2024-09-10

3. Can arsenic do anything good? Arsenic nanodrugs in the fight against cancer – last decade review;Talanta;2024-08

4. Diagnosis and management of acute promyelocytic leukemia: Brazilian consensus guidelines 2024 on behalf of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy;Hematology, Transfusion and Cell Therapy;2024-05

5. Superiority of anthracycline‐free treatment in standard‐risk acute promyelocytic leukemia: A systematic review and comparative epidemiological analysis;Cancer Reports;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3